Refractory Cytopenia with Multilineage Dysplasia (RCMD)
Clinical signs
- dysplastic changes are present in more than 10% of cells from two or more lineages
- prognosis: about 11% of patients develop AML, median survival time is approx. 33 months
- there are fewer than 5% of myeloblasts in the bone marrow
- bicytopenia or pancytopenia
- the number of ringed sideroblasts may be increased (RCMD-RS)
